French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday that the European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes in adults and children eight years and older with stage 2 T1D.
This approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use and is based on the TN-10 phase 2 study, which showed a median two-year delay in progression to stage 3 compared with placebo.
In the study, 57% of patients receiving Teizeild remained in stage 2 T1D versus 28% in the placebo group. The safety profile was consistent with prior trials, with the most common adverse events being transient lymphopenia in 75% of participants and rash in 36%.
Teizeild (known as Tzield outside the EU) is also approved in the US, UK, China, Canada, Israel, Saudi Arabia, UAE, and Kuwait. It represents the first disease-modifying therapy for T1D in the European Union.
Sanofi said that it has opted not to pursue a second application for Teizeild in recently diagnosed stage 3 T1D at this time. Other regulatory reviews are ongoing.
Merck partners with Isomorphic Labs on AI-driven oncology drug discovery
Dicot Pharma secures EU approval to advance LIB-01 phase 2b study
NFL Biosciences enrolls first participant in Phase 2 smoking cessation trial
Anixa Biosciences and Curia to finalise formulation of breast cancer vaccine for Phase 2 trial
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial